These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

762 related articles for article (PubMed ID: 21665242)

  • 41. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers.
    Sinicrope FA; Roddey G; Lemoine M; Ruan S; Stephens LC; Frazier ML; Shen Y; Zhang W
    Clin Cancer Res; 1998 May; 4(5):1251-61. PubMed ID: 9607584
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified.
    Ward RL; Turner J; Williams R; Pekarsky B; Packham D; Velickovic M; Meagher A; O'Connor T; Hawkins NJ
    J Pathol; 2005 Dec; 207(4):377-84. PubMed ID: 16175654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
    Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
    J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers.
    Kuismanen SA; Holmberg MT; Salovaara R; de la Chapelle A; Peltomäki P
    Am J Pathol; 2000 May; 156(5):1773-9. PubMed ID: 10793088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Challenges in the identification of MSH6-associated colorectal cancer: rectal location, less typical histology, and a subset with retained mismatch repair function.
    Klarskov L; Holck S; Bernstein I; Okkels H; Rambech E; Baldetorp B; Nilbert M
    Am J Surg Pathol; 2011 Sep; 35(9):1391-9. PubMed ID: 21836479
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B.
    Asaka S; Arai Y; Nishimura Y; Yamaguchi K; Ishikubo T; Yatsuoka T; Tanaka Y; Akagi K
    Carcinogenesis; 2009 Mar; 30(3):494-9. PubMed ID: 19147861
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
    Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
    Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Colorectal carcinomas with high microsatellite instability: defining a distinct immunologic and molecular entity with respect to prognostic markers.
    Edmonston TB; Cuesta KH; Burkholder S; Barusevicius A; Rose D; Kovatich AJ; Boman B; Fry R; Fishel R; Palazzo JP
    Hum Pathol; 2000 Dec; 31(12):1506-14. PubMed ID: 11150376
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation.
    Leung SY; Yuen ST; Chan TL; Chan AS; Ho JW; Kwan K; Fan YW; Hung KN; Chung LP; Wyllie AH
    Oncogene; 2000 Aug; 19(35):4079-83. PubMed ID: 10962567
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers.
    Mutch DG; Powell MA; Mallon MA; Goodfellow PJ
    Am J Obstet Gynecol; 2004 Apr; 190(4):935-42. PubMed ID: 15118616
    [TBL] [Abstract][Full Text] [Related]  

  • 53. p53 immunostaining cannot be used to predict TP53 mutations in gastric cancer: results from a large Central European cohort.
    Schoop I; Maleki SS; Behrens HM; Krüger S; Haag J; Röcken C
    Hum Pathol; 2020 Nov; 105():53-66. PubMed ID: 32971129
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.
    Baba Y; Nosho K; Shima K; Freed E; Irahara N; Philips J; Meyerhardt JA; Hornick JL; Shivdasani RA; Fuchs CS; Ogino S
    Clin Cancer Res; 2009 Jul; 15(14):4665-73. PubMed ID: 19584150
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Presence of Twist1-positive neoplastic cells in the stroma of chromosome-unstable colorectal tumors.
    Celesti G; Di Caro G; Bianchi P; Grizzi F; Basso G; Marchesi F; Doni A; Marra G; Roncalli M; Mantovani A; Malesci A; Laghi L
    Gastroenterology; 2013 Sep; 145(3):647-57.e15. PubMed ID: 23684708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.
    Kleist B; Meurer T; Poetsch M
    Tumour Biol; 2017 Mar; 39(3):1010428317692246. PubMed ID: 28345467
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases.
    Sturm I; Köhne CH; Wolff G; Petrowsky H; Hillebrand T; Hauptmann S; Lorenz M; Dörken B; Daniel PT
    J Clin Oncol; 1999 May; 17(5):1364-74. PubMed ID: 10334520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Microsatellite instability and B-type Raf proto-oncogene mutation in colorectal cancer: Clinicopathological characteristics and effects on survival.
    Batur S; Vuralli Bakkaloglu D; Kepil N; Erdamar S
    Bosn J Basic Med Sci; 2016 Nov; 16(4):254-260. PubMed ID: 27131021
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between MDM2 and p53 alterations in colorectal cancer and their involvement and prognostic value in the Tunisian population.
    Chaar I; Amara S; Khiari M; Ounissi D; Dhraif M; Ben Hamida AE; Gharbi L; Mzabi S; Bouraoui S
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):228-36. PubMed ID: 22914606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.